Brian O Mahony/X
Apr 26, 2026, 11:55
Brian O Mahony: Pierce Highlights Unique Inhibitor Cases in AAV-ET3 FVIII Gene Therapy Trial
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
”Pierce on Gene Therapy safety WFH Congress 2026 AAV-ET3 FVIII Human Porcine hybrid Gene Therapy trial in US.
Both participamts developed inhibitors.
These are the only inhibitors seen to date in all the haemophilia clinical trials.”
Stay updated with Hemostasis Today.
-
Apr 26, 2026, 11:51Mavis Agnes Kisakye: A Patient Story That Shows the Power of Humanitarian Aid
-
Apr 26, 2026, 11:38Ney Carter Borges: Perioperative Cardiovascular Medication Management in Noncardiac Surgery
-
Apr 26, 2026, 11:25Giacomo Centenaro: I Arrived to Represent My Country and Community at WFH 2026
-
Apr 26, 2026, 11:14Ali H. Hajeer: A New Tool to Align HLA Alleles with Serologic Classifications
-
Apr 26, 2026, 11:10Helen YeonJu Chung: Reflections from My 1st World Federation of Hemophilia Congress
-
Apr 26, 2026, 10:44Regan Bucciol: Unforgettable Science and Mentorship Moments at ISLH 2026
-
Apr 26, 2026, 10:21Aynetu Girma Moges: Major Cardiovascular Changes in Pregnancy
-
Apr 26, 2026, 07:10Mouna Sassi: Viscoelastic Evidence of Altered Clot Stability in Pediatric Edoxaban Overdose
-
Apr 26, 2026, 07:02Matías J. Alet: Reflections on Stroke Care and Brain-Heart Interaction at Stroke Congress 2026